Who
John Brendan Doyle
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Cognition Therapeutics; Chief Financial Officer, Chiasma.
In numbers
- Trades disclosed
- 24
- Buys
- 1
- Sells
- 0
- Bought
- $23K
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 19 Jan 2021
- Last trade
- 1 May 2026
- Last filed
- 4 May 2026
Companies traded
Activity over time
1 Apr – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 May 2026filed 4 May 2026 | CGTX Cognition TherapeuticsBiotechnology | SEC FORM 4 Code F | $11K8,567 at $1.28 | filing |
| 1 May 2026filed 4 May 2026 | CGTX Cognition TherapeuticsBiotechnology | SEC FORM 4 Code F | $11K8,567 at $1.28 | filing |
| 16 Apr 2026filed 20 Apr 2026 | CGTX Cognition TherapeuticsBiotechnology | SEC FORM 4 Bought | $11K10,000 at $1.13 | filing |
| 16 Apr 2026filed 20 Apr 2026 | CGTX Cognition TherapeuticsBiotechnology | SEC FORM 4 Bought | $11K10,000 at $1.13 | filing |
| 15 Feb 2026filed 18 Feb 2026 | CGTX Cognition TherapeuticsBiotechnology | SEC FORM 4 Code F | $1,7471,560 at $1.12 | filing |
| 15 Feb 2026filed 18 Feb 2026 | CGTX Cognition TherapeuticsBiotechnology | SEC FORM 4 Code F | $1,7471,560 at $1.12 | filing |
| 4 Feb 2026filed 5 Feb 2026 | CGTX Cognition TherapeuticsBiotechnology | SEC FORM 4 Code F | $28K26,921 at $1.03 | filing |
| 4 Feb 2026filed 5 Feb 2026 | CGTX Cognition TherapeuticsBiotechnology | SEC FORM 4 Code F | $28K26,921 at $1.03 | filing |
| 3 Feb 2026filed 5 Feb 2026 | CGTX Cognition TherapeuticsBiotechnology | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 3 Feb 2026filed 5 Feb 2026 | CGTX Cognition TherapeuticsBiotechnology | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 18 Dec 2025filed 22 Dec 2025 | CGTX Cognition TherapeuticsBiotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 18 Dec 2025filed 22 Dec 2025 | CGTX Cognition TherapeuticsBiotechnology | SEC FORM 4 Code F | $14K9,360 at $1.50 | filing |
| 29 Jul 2025filed 31 Jul 2025 | CGTX Cognition TherapeuticsBiotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 29 Jul 2025filed 31 Jul 2025 | CGTX Cognition TherapeuticsBiotechnology | SEC FORM 4 Code F | $6,2719,360 at $0.67 | filing |
| 1 May 2025filed 2 May 2025 | CGTX Cognition TherapeuticsBiotechnology | SEC FORM 4 Code F | $4,3619,692 at $0.45 | filing |
| 15 Feb 2025filed 18 Feb 2025 | CGTX Cognition TherapeuticsBiotechnology | SEC FORM 4 Code F | $1,0171,723 at $0.59 | filing |
| 4 Feb 2025filed 4 Feb 2025 | CGTX Cognition TherapeuticsBiotechnology | SEC FORM 4 Code A | —295,000 at $0.00 | filing |
| 1 May 2024filed 3 May 2024 | CGTX Cognition TherapeuticsBiotechnology | SEC FORM 4 Code F | $17K8,699 at $1.95 | filing |
| 15 Feb 2024filed 20 Feb 2024 | CGTX Cognition Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 15 Feb 2024filed 20 Feb 2024 | CGTX Cognition TherapeuticsBiotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
News
Cognition Therapeutics (NASDAQ:CGTX) Stock Falls 2% – Here's WhyCGTX · dailypolitical.com · 10 Oct 2026
0 headlines in the last 90 days name John Brendan Doyle; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.